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The recent successes in the immunotherapy field
demonstrate that a successful immune response to can-
cer can lead to meaningful anti-tumor responses. Anti-
bodies blocking immune checkpoint molecules (e.g.
CTLA4, and PD-1) lead to effective T cell responses
especially in tumors that are immune active.
Immune cells that have not received as much atten-
tion in cancer immunotherapy are neutrophils. Neutro-
phils are the most abundant white blood cells, which
protect us from microbial infections. They are the first
line of innate defense: they arrive early on in the course
of infection, phagocytose, and release the content of
their granules, including reactive oxygen species and
enzymes. Neutrophils also communicate with other
immune cells, such as macrophages, dendritic cells, and
T cells, by releasing cytokines and chemokines.
There has long been a call to recruit these profes-
sional killers to fight cancer. However, an approach that
mediates the recruitment of neutrophils has to lead to
acute as opposed to chronic inflammation to overcome
the suppressive environment that tumors surround
themselves with.
We have developed a novel immunotherapy platform
technology, termed mAbXcite, which directs and activates
neutrophils to kill cancer cells in a targeted manner. The
targeting is achieved by using monoclonal antibodies that
are chemically linked to beta-1,6-glucan, a saccharide
found on the cell walls of fungal species which recruits
and activates neutrophils. The resulting mAb construct
attracts mediators of acute inflammation, notably neutro-
phils, leading to rapid destruction of cancer cells.
We will present proof-of concept of the mAbXcite tech-
nology using two validated antibodies, the anti-Her2 Tras-
tuzumab and the anti-EGFR Cetuximab. In preclinical
xenograft models, these mAbXcite constructs demonstrate
significantly greater efficacy than the original antibody in
resistant tumor models. Furthermore, some mice show
complete regressions and do not grow tumors upon rechal-
lenge, suggesting a long term immune response. We will
also provide pharmacodynamics results, primarily neutro-
phil infiltration by histology and live imaging, as well as
pharmacokinetics results, demonstrating that the linked oli-
gosaccharide is stable and is not affecting the half-life of the
antibodies.
This novel immunotherapy platform is suitable for per-
ipheral membrane targets that are overexpressed on
tumors, and does not require antibody internalization. The
unique mechanism of action of recruiting and activating
neutrophils against cancer could be synergistic with other
immunotherapeutic approaches.
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